group of drugs, called angiogenesis inhibitors, have already been
developed as potential treatments by preventing the formation of new
blood vessels. Tumours need new blood vessels to help them grow and
spread, but these drugs have not been as successful as hoped. The
researchers believe that vascular mimicry could be one of the reasons
“If we can
conclusively demonstrate that this retrotransposon is linked to cancer
in soft-shell clams in the field, we can then use these sequences [as
diagnostic markers] in order to prevent outbreaks.”
That was it:
two transmissible tumours. Now, there’s a third—and perhaps more on the
way. “Maybe this is way more common than we thought in invertebrates,
and especially in marine ones,” says Stephen Goff, who led the study.
“We’re all sitting in the same ocean here.”
analysis led by UT Southwestern Medical Center researchers suggests that
most pancreatic cancers harbor genetic alterations that could be
targeted by existing drugs, using their genetic features as a roadmap
If the F.D.A.
panel agrees, it will be the first time since Congress passed the law
requiring warning labels in 1965 that any product has gotten a gentler
warning. Such a decision could blaze a trail for a far more popular
smokeless product, the e-cigarette, which has divided public health
experts since appearing on the market.
The US Food
and Drug Administration (FDA) has put the finishing touches on two
policies intended to expedite access to potentially life-saving devices
meant for patients with life-threatening diseases or conditions.
major initiative, it will be harder to make progress because the groups
focused on genomically targeted therapy and the checkpoint blockade
researchers will largely stay in their own camps.”
cover story on mouse avatars, and much of the issue’s other content,
focuses on the remarkable progress made in designing cancer therapies
that embody the ideals of precision, or personalized,
medicine—increasingly patient- and tumor-specific, and often less toxic
to normal cells.
works by inhibiting the activity of receptor tyrosine kinases which are
involved in both normal cellular function and in pathologic processes.
Exelixis expects to release top line results from the current study of
the drug sometime in the second quarter this year.
is the subject of METEOR, an ongoing phase 3 pivotal trial in patients
with metastatic RCC who have experienced disease progression following
treatment with at least one VEGFR tyrosine kinase inhibitor.
its lead candidate--a bispecific antibody with enhanced ADCC
(antibody-dependent cellular cytotoxicity) targeting HER2 and HER3--into
a Phase I/II trial in patients with solid tumors earlier this year.
The MRC and
NIHR invite applications through the Methodology Research Programme to
conduct research into the possibility of creating a measure of quality
of life or wellbeing, which would have utility across health and social
evaluation commissioned by one of the co-authors of the study protocol,
patient follow-up, and study results published in the manuscript has led
to the conclusion that 6 of the 30 patients were invented and that
follow-up studies in 10 of the 30 patients were not performed or
contradict patient data published in the manuscript.
Staff at the
hospital where five-year-old Ashya King was treated for brain cancer
before he was taken abroad by his parents have spoken about the
“outpouring of hatred” they received – but said they would act in the
same way if the situation arose again.